Literature DB >> 22497632

Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Yun-Hsuan Lee1, Chia-Yang Hsu, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Rheun-Chuan Lee, Yi-You Chiou, Teh-Ia Huo, Shou-Dong Lee.   

Abstract

BACKGROUND AND AIM: Renal insufficiency (RI) often coexists with hepatocellular carcinoma (HCC) and predicts a poor outcome in patients receiving transarterial chemoembolization (TACE). The modification of diet in renal disease (MDRD) and chronic kidney disease epidemiology collaboration (CKD-EPI) equations are used to provide estimated glomerular filtration rate (eGFR). This study aimed to determine a prognsotic renal surrogate for outcome prediction in HCC patients receiving TACE.
METHODS: A total of 684 patients with HCC undergoing TACE were retrospectively analyzed. The prognostic ability between the MDRD and CKD-EPI equation was compared by the Akaike information criterion (AIC).
RESULTS: Patients were categorized by eGFR into > 60, 30-60 and < 30 mL/min per 1.73 m(2) (equivalent to CKD stages 1-2, 3, and 4-5, respectively) groups. The eGFR generated by the MDRD equation had a better predictive accuracy by having a lower AIC score (3234.5) compared to the CKD-EPI equation (3236.7). The adjusted risk ratio for patients with eGFR 30-60 mL/min per 1.73 m(2) by the MDRD was 1.313 (P = 0.041) compared with patients with eGFR > 60 mL/min per 1.73 m(2) in the multivariate Cox model. The eGFR defined by the MDRD equation consistently had better prognostic ability when patients were stratified by the Child-Turcotte-Pugh score of 5 and > 5 and Cancer of the Liver Italian Program score 0 to 1 and > 1.
CONCLUSIONS: The eGFR according the MDRD equation may provide better prognostic accuracy than the CKD-EPI equation independent of liver functional reserve and tumor staging, and is a more feasible renal surrogate for outcome prediction in CKD stage 1-3 HCC patients receiving TACE.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22497632     DOI: 10.1111/j.1440-1746.2012.07151.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC).

Authors:  Katsumi Hayakawa; Masato Tanikake; Toshihiko Kirishima; Naomi Yoshinami; Hiroyuki Shintani; Eiji Yamamoto; Taisuke Morimoto
Journal:  Eur Radiol       Date:  2014-02-13       Impact factor: 5.315

2.  Hepatocellular carcinoma in patients with chronic kidney disease.

Authors:  Chern-Horng Lee; Sen-Yung Hsieh; Ja-Liang Lin; Maw-Sen Liu; Tzung-Hai Yen
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

3.  Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond Milan criteria independent of performance status.

Authors:  Po-Hong Liu; Yun-Hsuan Lee; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo
Journal:  J Gastrointest Surg       Date:  2014-05-29       Impact factor: 3.452

4.  Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff?

Authors:  Chia-Yang Hsu; Po-Hong Liu; Yun-Hsuan Lee; Cheng-Yuan Hsia; Yi-Hsiang Huang; Han-Chieh Lin; Yi-You Chiou; Fa-Yauh Lee; Teh-Ia Huo
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

5.  Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model.

Authors:  Chia-Yang Hsu; Yun-Hsuan Lee; Po-Hong Liu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Han-Chieh Lin; Yi-You Chiou; Fa-Yauh Lee; Teh-Ia Huo
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.